EASD: Merck’s Investigational Once-Weekly DPP-4 Inhibitor Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes oktober 7, 2012 3:25 e m Läs mer »
EASD: Once a Year Exenatide (GLP-1-analogue ”Byetta”) Introduced at EASD oktober 7, 2012 3:23 e m Läs mer »
EASD: NDR Sweden; Increasing Physical Activity Slashes CV Events, Deaths by 66% for Type 2’s oktober 7, 2012 3:19 e m Läs mer »
EASD. EASD: New EASD/ADA Position Paper Shifts Treatment Goals with 7 Key Points oktober 7, 2012 3:12 e m Läs mer »
EASD. Ny analyse viser, at Victoza® (liraglutid) har større effekt ved tidlig brug i behandling af type 2-diabetes oktober 5, 2012 5:22 f m Läs mer »
Hur tar vi initiativet i kampen mot diabetes?. Världsdiabetesdagen 14 nov. Symposium Sthlm Dagens Medicin oktober 4, 2012 3:29 e m Läs mer »
